CHP
ENTA icon

Cable Hill Partners’s Enanta Pharmaceuticals ENTA Stock Holding History

Cable Hill Partners’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-168
Closed -$4K – 911
2016
Q2 		$4K Hold
168
– – ﹤0.01% 542
2016
Q1 		$5K Buy
168
+149
+784% +$4.15K ﹤0.01% 475
2015
Q4 		$1K Sell
19
-187
-91% -$6.09K ﹤0.01% 627
2015
Q3 		$8K Hold
206
– – 0.01% 406
2015
Q2 		$10K Hold
206
– – 0.01% 440
2015
Q1 		$6K Buy
206
+13
+7% +$506 ﹤0.01% 525
2014
Q4 		$10K Buy
+193
New +$8.64K 0.01% 426

Other funds holding ENTA

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AL
AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Cable Hill Partners's ENTA Position: Q3 2016 in Review

Cable Hill Partners sold out of Enanta Pharmaceuticals (ENTA) in Q3 2016, closing a stake of 168 shares — an estimated $4K sold.

Cable Hill Partners first reported a position in ENTA in Q4 2014 and held it in 7 quarters. The position peaked at $10K in Q2 2015. 136 funds tracked by Wall St. Rank hold ENTA as of Q3 2016.

  • Cable Hill Partners reported no remaining Enanta Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Cable Hill Partners sold 168 Enanta Pharmaceuticals shares in Q3 2016, an estimated $4K.
  • Cable Hill Partners first reported a position in Enanta Pharmaceuticals in Q4 2014 and held it in 7 quarters.
  • Cable Hill Partners's Enanta Pharmaceuticals position peaked at $10K in Q2 2015.
  • 136 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2016.

Based on Cable Hill Partners's 13F filing for Q3 2016, filed 16 Nov 2016.